Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease. Correlation with disease activity.
The activation of T lymphocyte is accompanied by the release of soluble interleukin-2 receptors (sIL-2R) which can be assessed in biological fluids. A prospective study of the dynamic changes in sIL-2R levels was performed in the serum of 10 patients undergoing a medical treatment for Graves' disease. All patients received carbimazole during the study and, when necessary, L-thyroxine to compensate hypothyroidism. sIL-2R levels were measured before (M0) and after the 1st (M1), 3rd (M3) and 6th month (M6) of treatment. The levels of sIL-2R were high at M0 and M1, and decreased significantly between M1 and M3 (p = 0.03). At M0, the levels of sIL-2R were highly correlated with triiodothyronine (T3) levels (p = 0.0003), early [131I] uptake (p = 0.007) and, to a lesser degree, with anti-thyrotropin receptor antibody levels (p = 0.02). At M6, no correlation was found anymore. We conclude that sIL-2R levels are increased in patients with untreated Graves' disease. They are highly correlated with the markers of Graves' disease activity and decrease during medical treatment.
Weryha
G
G
Clinique Endocrinologique, CHU de Nancy, Vandoeuvre-lès-Nancy, France.
Gobert
B
B
Leclère
J
J
Béné
M C
MC
Faure
G
G
Hartemann
P
P
D000328:Adult; D001323:Autoantibodies / Q000097:blood; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D011989:Receptors, Thyrotropin / Q000276:immunology; D014284:Triiodothyronine / Q000097:blood
D001323:Autoantibodies; D007457:Iodine Radioisotopes; D015375:Receptors, Interleukin-2; D011989:Receptors, Thyrotropin; D014284:Triiodothyronine; D002231:Carbimazole